Alnylam gives 12-month patisiran update
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) released updated 12-month data from an ongoing Phase II open-label extension study of patisiran to treat familial amyloidotic polyneuropathy (FAP). Alnylam said patisiran-treated patients who reached the 12-month endpoint (n=20) had a mean 2.5-point decrease in modified Neuropathy Impairment Score (mNIS+7). The company estimated that untreated FAP patients with similar baseline characteristics typically experience a 13- to 18-point increase in mNIS+7 after 12 months, based on historical data. Alnylam presented the 12-month data at this week's American Academy of Neurology meeting.
The company also released complete six-month results from the trial, showing that patients receiving patisiran had a mean 1.4-point decrease in mNIS+7. Alnylam said the updated data are consistent with previously announced results (see BioCentury, Oct. 20, 2014). ...